mortality/aging
|
• following tamoxifen treatment, all mice are dead by 18 weeks of observation unlike untreated mice and Ptch1tm1Mps heterozygotes
|
neoplasm
|
• following tamoxifen treatment, mice exhibit macroscopic basal cell carcinomas (BBC) where as all other mice develop BBC tumors at 8 weeks
|
|
• present without tamoxifen treatment (average number 3)
• following tamoxifen treatment, the multiplicity of tumors is increased (average number 7)
• mostly confined to rear thigh and abdominal wall
• following tamoxifen treatment, tumors are detected in skeletal muscle of the head, neck, tongue and paratesticular regions
• following tamoxifen treatment at P10, age of onset is accelerated to week 5 compared to week 9 in untreated mice
|
|
• found in 27% of mice and 40% of mice following tamoxifen treatment
|
digestive/alimentary system
|
• diverticular harmatomatous lesions in the intestine occur at a higher rate following treatment with tamoxifen (20% without treatment and 80% following treatment)
|
|
• diverticular harmatomatous lesions in the stomach occur at a higher rate following treatment with tamoxifen (less than 5% of mice after treatment)
|
endocrine/exocrine glands
|
• cystic metaplastic lesions are observed with increased frequency following tamoxifen treatment
|
integument
|
• following tamoxifen treatment, mice exhibit macroscopic basal cell carcinomas (BBC) where as all other mice develop BBC tumors at 8 weeks
|
nervous system
|
• found in 27% of mice and 40% of mice following tamoxifen treatment
|
muscle
|
• present without tamoxifen treatment (average number 3)
• following tamoxifen treatment, the multiplicity of tumors is increased (average number 7)
• mostly confined to rear thigh and abdominal wall
• following tamoxifen treatment, tumors are detected in skeletal muscle of the head, neck, tongue and paratesticular regions
• following tamoxifen treatment at P10, age of onset is accelerated to week 5 compared to week 9 in untreated mice
|